Glycerophospholipids are main components of cellular membranes and have numerous structural and functional roles to regulate cellular functions. Polyunsaturated fatty acids, such as arachidonic acid and eicosapentaenoic acid, are mainly located at the sn-2, but not the sn-1 position of glycerophospholipids in an asymmetrical manner and the fatty acid compositions at both the sn-1 and sn-2 positions differ in various cell types and tissues. Asymmetry and diversity of membrane glycerophospholipids are generated in the remodelling pathway (Lands' cycle), which are conducted by the concerted actions of phospholipases A 2 (PLA 2 s) and lysophospholipid acyltransferases (LPLATs). The Lands' cycle was first reported in the 1950s. While PLA 2 s have been well characterized, little is known about the LPLATs. Recently, several laboratories, including ours, isolated LPLATs that function in the Lands' cycle from the 1-acylglycerol-3-phosphate O-acyltransferase family and the membrane bound O-acyltransferases family. In this review, we summarize recent studies on cloning and characterization of LPLATs that contribute to membrane asymmetry and diversity.
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Cells are encapsuled by membranes, which mainly contain phospholipids, cholesterol and proteins as primary constituents. Membrane glycerophospholipids are important not only as structural and functional components of cellular membranes but also as precursors of various lipid mediators such as platelet-activating factor (PAF) 4 and eicosanoids (1, 2) . Polyunsaturated fatty acids (PUFAs) are mainly located at the sn-2 position, but not at the sn-1, position of glycerophospholipids in an asymmetrical manner. Each tissue and cell type maintains a distinct content and composition of the various classes of glycerophospholipids such as phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG) and cardiolipin (CL) (35) . Using acyl-CoAs as donors, glycerophospholipids are formed from glycerol-3-phosphate (G3P) by the de novo pathway (also called the Kennedy pathway) originally described by Kennedy in 1956 (6) . However, in the Kennedy pathway, highly diverse fatty acid compositions may be generated at the sn-2 position of PA, but not of PC, PE, PS, PI, PG or CL. This diversity and asymmetry in phospholipids other than PA cannot be fully explained by the Kennedy pathway. Rapid turnover of the sn-2 acyl moiety of glycerophospholipids was originally described by Lands as the remodelling pathway (Lands' cycle) (7) and is attributed to the concerted and coordinated actions of phospholipases A 2 (PLA 2 s) and lysophospholipid acyltransferases (LPLATs) (Figs 1 and 2) (2, 8, 9) . Recently, LPLATs were identified from the 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT) and the membrane bound O-acyltransferase (MBOAT) families (Table I) (10) . Dr Lands asked in his review 'Which enzymes distinguish between saturated and unsaturated acyl chains?' (9) . The recent discovery of LPLATs can answer part of his important questions, however, we need further experiments to elucidate the biological roles of LPLATs. In this review, we will mainly summarize the biochemical characteristics of LPLATs.
Because several groups have independently cloned the same LPLAT or registered different names for the same enzyme based on activity or sequence homology, many of the LPLATs have been assigned multiple names. Their nomenclatures are summarized in Table I .
LPLATs from the AGPAT Family
LPAATs from the AGPAT family In the Kennedy pathway of glycerophospholipid biosynthesis, lyso-PA (LPA) is first formed from G3P by G3P acyltransferases (GPATs). Currently, four mammalian GPATs have been cloned and summarized in reviews (10, 11) . Next, LPA is converted to PA by LPAATs.
To date, three LPA acyltransferases (LPAATs; LPAAT1, 2 and 3) have been cloned and characterized from the AGPAT family, and two additional LPAAT candidates (AGPAT4 and 5) have also been reported (1012). LPAAT3 is upregulated in testis age dependently (12) . Interestingly, LPAAT3 showed LPAAT activity with preference for polyunsaturated fatty acyl-CoAs, such as 22 : 6-CoA, although the enzyme is in the Kennedy pathway (13) . The induction of LPAAT3 during germ cell development might contribute to the accumulation of PUFAs in testicular phospholipids, thereby possibly affecting proper sperm cell differentiation and maturation (13, 14) .
Lyso-CL acyltransferase 1 and lyso-PG acyltransferase 1 from the AGPAT family CL is the only known dimeric glycerophospholipids and normally contains four linoleoyl group (C18 : 2) fatty acyl chains. CL is remodelled from dilyso-CL and monolyso-CL by lyso-CL acyltransferase (LCLAT). Mouse LCLAT1 (also called ALCAT1 by Cao et al. 2004 ) was identified and found to possess LCLAT activity (15) . LCLAT1 also possesses lyso-PI acyltransferase (LPIAT) and lyso-PG acyltransferase (LPGAT) activities (16) . A putative LPI recognition site was identified by site directed mutagenesis. In that report, siRNA of LCLAT1 decreased LPIAT and LPGAT activities, but not LCLAT activity indicating that LCLAT1 functions as LPIAT and LPGAT enzymes in vivo (16) . However, another group showed LCLAT1 is localized in the mitochondria associated membrane (MAM) as an LCLAT enzyme (17) . CL remodelling is believed to play an important role in the maintenance of normal heart functions. Defective CL is associated with Barth syndrome, a family disease caused by mutations of putative acyltransferase genes that manifests itself as cardiomyopathy and skeletal myopathy (18) . LCLAT1 also possesses activity to incorporate 18 : 0-CoA into the sn-1 position of LPI (19) . PG is a precursor for the synthesis of CL. In the Lands' cycle, PG is synthesized from LPG by LPGAT enzyme. LPGAT1 was reported as an LPGAT enzyme in 2004 (20) . LPGAT1 also possesses the AGPAT motifs. Human LPGAT1 showed a clear preference for 16 : 0, 18 : 0 and 18 : 1-CoAs as donors and is widely expressed in several tissues (20) . Identification of LPLATs in Lands' cycle started with these LCLAT1 and LPGAT1.
Lyso-PC acyltransferase 1 from the AGPAT family We and Chen et al. independently discovered lyso-PC acyltransferase (LPCAT)1, which synthesizes dipalmitoyl-PC (21, 22) . We termed the enzyme LPCAT1, as this was the first case of isolation of the enzyme with LPCAT activity. LPCAT1 is mainly expressed in lung, especially in alveolar type II cells and its mRNA is robustly increased during the perinatal period. Alveolar type II cells produce pulmonary surfactant, which prevents alveolar collapse, small airway closure and alveolar flooding by decreasing surface tension. Pulmonary surfactant deficiency is recognized to be an important contributing factor in the pathogenesis of infant respiratory distress syndrome (IRDS), acute respiratory distress syndrome (ARDS), bronchial asthma and bronchiolitis (23) . Dipalmitoyl-PC is a major component of pulmonary surfactant. Thus, LPCAT1 may synthesize the PC of pulmonary surfactant and play a critical role in respiratory physiology. Recently, several groups reported LPCAT1 function in the lung and retina (2426) (described in section 'Analyses of LPLATs in Cells and Mice' and 'Regulation of LPLATs'). LPCAT1 can also produce PAF by its lyso-PAF acetyltransferase activity in vitro Other names are mainly collected from literatures and Homologene at the NCBI web site, http://www.ncbi.nlm.nih.gov/homologene/. M, mitochondria; G, Golgi; LD, lipid droplet. (27) . Further studies are required to uncover the biological roles of PAF generated by LPCAT1.
LPCAT2 from the AGPAT family: a PAF biosynthetic enzyme LPCAT2 was identified by our group as the longsought lyso-PAF acetyltransferase involved in PAF biosynthesis in the remodelling pathway (28) . LPCAT2 expression is mainly observed in inflammatory cells such as peritoneal macrophages. Induction and activation of LPCAT2 is regulated by extracellular stimuli such as a lipopolysaccharide (described in section 'Regulation of LPLATs'). In contrast to LPCAT2, LPCAT1 was neither activated nor upregulated by lipopolysaccharide stimulation. Thus, two distinct lyso-PAF acetyltransferases are present: one is a constitutively expressed lyso-PAF acetyltranferase, LPCAT1, and the other is an inducible lyso-PAF acetyltranferase, LPCAT2. This relationship is similar to cyclooxygenase 1 and 2, which are constitutively expressed and inducible enzymes, respectively (29) . Therefore, specific lyso-PAF acetyltransferase activity inhibitors discriminating between LPCAT1 and LPCAT2 may be better anti-inflammatory drugs in PAF related diseases than PAF receptor antagonists, since such drugs are expected to inhibit PAF production only under inflammatory conditions. Moreover, it is important to distinguish acetyltransferase (PAF) and acyltransferase (PC) activities of LPCAT1 and LPCAT2. Surprisingly, LPCAT2 also possesses lyso-PAF acyltransferase activity with preference for 20 : 4-CoA. Thus, LPCAT2 is not only a critically important enzyme in the biosynthesis of PAF (lyso-PAF acetyltransferase activity) but also in membrane homeostasis of inflammatory cells (LPC acyltransferase activity). It will be important to characterize both acetyltransferase and acyltransferase activities of LPCAT2, including identification of binding sites for each substrate (acetyl-CoA and arachidonoyl-CoA). Both LPCAT1 and LPCAT2 are localized in the endoplasmic reticulum (ER) (21, 28) and are reported to be found on the surface of lipid droplets as well (30) .
Lyso-PE acyltransferase2 from the AGPAT family Lyso-PE acyltransferase (LPEAT)2 possesses LPEAT, LPGAT, lyso-PS acyltransferase (LPSAT) and LPCAT activities with 18 : 1-CoA or 20 : 4-CoA as acyl donors, however, its siRNA decreased only LPEAT activity in HEK293T cells (31) . The enzyme is expressed mainly in the brain and the authors propose that LPEAT2 is an important enzyme in the biogenesis of brain PE. However, the biochemical activities of LPEAT2 from the literature are not consistent with brain PE compositions. Confusingly, LPEAT2 is also called LPCAT4 (Table I) .
LPLATs from the MBOAT Family
LPIAT1 from the MBOAT family LPIAT1 (also called MBOA-7, MBOAT7 and LRC4) was identified as the first LPIAT, which prefers 20 : 4-CoA and 20 : 5-CoA as donors (32) . A predicted active site residue, His350 within a long hydrophobic region, was identified by site-directed mutagenesis of human LPIAT1. An LPIAT1 mutant of Caenorhabditis elegans showed a 'bags of worms' phenotype whereby the embryos hatched within the mother, leaving a cuticle sack that contained multiple wriggling larvae. In LPIAT1 mutant of C. elegans, PI containing arachidonic acid and eicosapentaenoic acid were reduced. Thus, it has been assumed that specific PI molecular species are critical for normal phosphoinositide.
LPCAT3, LPCAT4 and LPEAT1 from the MBOAT family LPCAT3 (called MBOAT5) was discovered by two independent groups including ours (33, 34) . Mouse LPCAT3 mRNA is ubiquitously expressed and showed LPCAT, LPEAT and LPSAT activities that utilize polyunsaturated fatty acyl-CoAs such as 20 : 4-CoA and 18 : 2-CoA (Fig. 2) . Moreover, we showed that LPCAT4 (originally called MBOAT2) possesses LPCAT and LPEAT activities, whereas LPEAT1 (also called MBOAT1) exhibits LPEAT and LPSAT activities (33) . Both LPCAT4 and LPEAT1 preferred 18 : 1-CoA as a donor. Mouse LPCAT4 mRNA is highly expressed in epididymis, brain, testis and ovary, and mouse LPEAT1 mRNA is highly expressed in stomach, epididymis and colon. Based on the apparent K m and V max values, LPCAT3 exhibited higher LPCAT activity than LPEAT and LPSAT activities. Similarly, LPCAT4 exhibited higher LPCAT activity than LPEAT activity. LPEAT1 showed similar activities for LPE and LPS.
Gijon et al. analysed the biochemical characteristics of human MBOAT enzymes (LPCAT3, LPCAT4, LPEAT1 and LPIAT1) by dual substrate choice acyltransferase assays (35) . Their assays showed substrate preferences of these enzymes, which are in agreement with previous reports.
AGPAT and MBOAT Motifs
Site-directed mutagenesis revealed four AGPAT motifs:
(1)HxxxxD, (2)GxxFxxR, 
Analyses of LPLATs in Cells and Mice
LPAAT3 is reported to be important for Golgi structure and function. LPAAT3 overexpression in cells slows the formation of Golgi membrane tubules, and LPAAT3 knockdown causes Golgi fragmentation and accelerated membrane trafficking (38) .
LCLAT1 overexpression in cells causes a decrease in CL containing linoleic acid, and an increase in PUFA containing CL. This leads to increased oxidative stress and causes mitochondrial dysfunction. LCLAT1 deficiency alleviates mitochondrial oxidation.
LCLAT1-KO mice are protected from diet-induced obesity, insulin resistance and hypertrophic cardiomyopathy (17, 39, 40) .
Mice expressing a hypomorphic allele of LPCAT1 (LPCAT1 gene trap mice) showed decreased saturated PC, and a higher perinatal mortality due to respiratory failure. This indicates that saturated PC produced by LPCAT1 is important for lung surfactant production (26) .
LPIAT1-KO mice expressed reduced arachidonic acid content in PI and PI phosphates, and showed abnormal brain morphology, delayed neural migration and reduced neurite outgrowth. LPIAT1-KO mice are significantly smaller than their littermates and are born less than the expected Mendelian frequency (41, 42) .
LPCAT3 knockdown in HEK293 cells induced apoptosis and altered cellular morphology (43) . Liver-specific knockdown of LPCAT3 in mice showed increased LPC, which led to decreased hepatic triglyceride levels, and increased triglyceride-rich lipoprotein production and apoB secretion (44) .
Regulation of LPLATs
LPCAT1 and LPAAT3 were upregulated during the perinatal period in the lung and the testis, respectively (12, 14, 22) . The expression patterns of these enzymes and their in vitro activities suggest that LPCAT1 may produce pulmonary surfactant lipids (mainly dipalmitoyl-PC) essential for respiration and that LPAAT3 may affect testis maturation (13, 14, 21, 22) . A mouse strain with a mutation in LPCAT1 (rd11) shows retinal degeneration and defect in visual function (24) . LPCAT1 mRNA level was significantly downregulated in the retina and the brain in response to the onset of diabetes in Ins2(Akita) and db/db mice, mouse models of type 1 and type 2 diabetes, respectively (25) . LPCAT1 was reported to be highly expressed in colorectal cancer, and LPCAT1 expression was also found to correlate with the progression of prostate cancer (45, 46) .
Before cloning of LPCAT2, biochemical characteristics of a lyso-PAF acetyltransferase enzyme have been well investigated. In mouse thioglycollate-induced macrophages, treatment with lipopolysaccharide (a Toll-like receptor 4, TLR4 agonist) for a long time (16 h) increased lyso-PAF acetyltransferase activity. Acute inflammatory stimulation with lipopolysaccharide for a short period of time (30 min) also enhances lyso-PAF acetyltransferase activity in the p38 MAP kinase-dependent manner (47) . After cloning, we reported that LPCAT2 was upregulated and activated under the same conditions (28) . We also identified a phosphorylated residue, Ser34, and the activity of LPCAT2 was enhanced by the phosphorylation of this amino acid residue (48) . LPCAT2 may be directly phosphorylated by MAP kinase-activated protein kinase 2 (MK2), which is a down stream molecule of p38 MAP kinase.
LPCAT2 expression was significantly elevated in spinal cords of mice with experimental allergic encephalomyelitis (EAE), which is a model of multiple sclerosis. In the CNS of EAE mice, the bloodbrain barrier has been broken and inflammatory cells have infiltrated in the CNS. As LPCAT2 is upregulated in activated macrophages and microglia, PAF is produced during nerve injury (49) . LPCAT2 mRNA is also reported to be upregulated in the ipsilateral spinal cord in a rat model of peripheral nerve injury (50) .
LPCAT3 is known to be induced by agonists for peroxisome proliferator-activator receptor a and liver X receptor (34, 51) . LPCAT3 is also induced during differentiation of 10T1/2 cells into adipocyte-like cells (52) . Treatment with fibrates leads to an increase in hepatic LPCAT3 and LPCAT4 expression (53) . In a model of non-alcoholic steatohepatitis, LPCAT1, LPCAT2, LPCAT3 and LPCAT4 were induced (54) .
Lithocholic acid exposure leads to an increase in hepatic LPEAT2 expression (55) . LCLAT1 expression is enhanced by oxidative stress (17) , hypertrophic cardiomyopathy (40) , and also during chronic muscle disuse (56) . Further studies are needed to clarify the biological importance of the regulation of theses LPLATs.
Conclusion
Both the Kennedy pathway and the Lands' cycle were reported in the 1950s. The enzymes in the Kennedy pathway were identified and investigated earlier than the LPLATs in the Lands' cycle, however, recently, several groups identified LPLATs functioning in the Lands' cycle, expanding the new field ( Fig. 1 ; Table I ). In this review, we summarized the ambiguous naming of LPLATs and attempted to clarify and standardize the nomenclature (see Table I ), however, finalization of a standard and rational nomenclature awaits a consensus by the international scientific committee. Biochemical characteristics of LPLATs were investigated in vitro assays. Recently, studies utilizing enzyme knockout mice and knock down cells have gradually uncovered the biological roles of LPLATs, and it is important to elucidate their regulation and functions in cells in the near future. Further studies will be needed to clarify the biological roles of these enzymes in vivo. Additional LPLATs contributing to the generation of membrane diversity may also exist. It will also be important to determine the functional coupling of acyl-CoA synthetases, phospholipases and LPLATs. Specific inhibitors are also important for candidates of drug development. Recent findings and studies of LPLATs are expanding and highlighting the LPLAT field. These advances will pave the way for novel understandings of the significance of membrane diversity and asymmetry.
